Li Hong-Xing, Zhang Cui, Zhang Kai, Liu Yi-Zhe, Peng Xiao-Xiao, Zong Qiang
Department of Neurosurgery, Shengli Oilfield Central Hospital, Dongying, Shandong, China.
Department of Otolaryngology, Shengli Oilfield Central Hospital, Dongying, Shandong, China.
Front Med (Lausanne). 2023 Apr 20;10:1137366. doi: 10.3389/fmed.2023.1137366. eCollection 2023.
The relationship between inflammatory bowel disease (IBD) and the risk of Parkinson's Disease (PD) has been investigated in several epidemiological studies. However, the results of these studies were inconclusive and inconsistent. We evaluated the potential relationship between IBD and PD risk by a meta-analysis.
Search the electronic databases PubMed, Embase and Cochrane databases from inception to November 30, 2022, to identify relevant studies that assess the risk of PD in patients with IBD. The cohort, cross-sectional, mendelian randomization and case-control studies that reported risk estimates of PD and IBD were included in our analysis. The random-effect model and fixed-effects model were used to calculate the summary relative risks (RRs) with 95% confidence intervals (CIs).
In total, 14 studies (nine cohort studies, two cross-sectional studies, two mendelian randomization studies and one case-control study) involving more than 13.4 million individuals were analyzed in our analysis. Our results suggested that the risk of PD in IBD patients is moderately increased, with the pooled RR was 1.17 (95% CI: 1.03-1.33, = 0.019). Omit of any single study from this analysis had little effect on the combined risk estimate. No evidence of publication bias was found. In the subgroup analysis, the combined RR was 1.04 (95% CI: 0.96, 1.12, = 0.311) for Crohn's disease (CD), and 1.18 (95% CI: 1.06, 1.31, = 0.002) for ulcerative colitis (UC). In addition, a significant association was identified in patients with IBD aged ≥ 60 years (RR = 1.22; 95% CI: 1.06-1.41, = 0.007), but not in age < 60 years (RR = 1.19; 95% CI: 0.58-2.41, = 0.639). Meanwhile, the meta-analysis results suggested a protective role for IBD medication use against PD development, with the RR was 0.88 (95% CI: 0.74, 1.04, = 0.126).
Our results indicated that patients with IBD had a moderately higher risk of PD compared to non-IBD individuals. Patients with IBD should be aware of the potential risks for PD, especially who were ≥ 60 years old.
多项流行病学研究探讨了炎症性肠病（IBD）与帕金森病（PD）风险之间的关系。然而，这些研究结果尚无定论且不一致。我们通过荟萃分析评估了IBD与PD风险之间的潜在关系。
检索电子数据库PubMed、Embase和Cochrane数据库，检索时间从建库至2022年11月30日，以确定评估IBD患者发生PD风险的相关研究。纳入报告了PD和IBD风险估计值的队列研究、横断面研究、孟德尔随机化研究和病例对照研究。采用随机效应模型和固定效应模型计算汇总相对风险（RRs）及95%置信区间（CIs）。
我们的分析共纳入14项研究（9项队列研究、2项横断面研究、2项孟德尔随机化研究和1项病例对照研究），涉及超过1340万人。我们的结果表明，IBD患者发生PD的风险适度增加，汇总RR为1.17（95%CI：1.03 - 1.33，P = 0.019）。从该分析中剔除任何一项研究对合并风险估计影响不大。未发现发表偏倚的证据。在亚组分析中，克罗恩病（CD）的合并RR为1.04（95%CI：0.96，1.12，P = 0.311），溃疡性结肠炎（UC）的合并RR为1.18（95%CI：1.06，1.31，P = 0.002）。此外，在年龄≥60岁的IBD患者中发现显著关联（RR = 1.22；95%CI：1.06 - 1.41，P = 0.007），而在年龄<60岁的患者中未发现（RR = 1.19；95%CI：0.58 - 2.41，P = 0.639）。同时，荟萃分析结果表明IBD药物使用对PD发生有保护作用，RR为0.88（95%CI：0.74，1.04，P = 0.126）。
我们研究结果表明，与非IBD个体相比，IBD患者发生PD的风险略高。IBD患者应意识到发生PD的潜在风险，尤其是年龄≥60岁的患者。
